Not Yet RecruitingNot Applicable

TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.

208 participantsStarted 2025-10-01

Plain-language summary

The investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the role of this treatment in modulating the systemic inflammatory response and its potential impact on 90- and 180-day morbidity and mortality and neurological outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients aged ≥18 years;
✓. Patients with suspected cardiogenic cardiac arrest;
✓. Patients with comatose state after ROSC (Glasgow Coma Scale \[GCS\] score \<9);
✓. Patients with Return of spontaneous circulation (ROSC) sustained for \>20 minutes;

Exclusion criteria

✕. Cardiac arrest due to trauma;
✕. Suspected or confirmed hemorrhagic or ischemic stroke;
✕. Pregnancy;
✕. Cardiac arrest without witnessed collapse;
✕. Admission body temperature \<30°C;
✕. Persistent cardiogenic shock (defined as systolic blood pressure \<90 mmHg despite aggressive intervention during screening);
✕. Any underlying disease with an expected survival of \<180 days;
✕. Pre-existing severe neurological dysfunction before cardiac arrest (e.g., Cerebral Performance Category \[CPC\] 3-4);

What they're measuring

30-day survival rate

Timeframe: 30 days after randomization.

Trial details

NCT IDNCT07176754

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-07-31

Contact for this trial

Qingbian Ma

15611908229 maqingbian@126.com

View on ClinicalTrials.gov More Cardiac Arrest (CA) trials